PP
MRNA icon

Pacifica Partners’s Moderna MRNA Stock Holding History

Pacifica Partners’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39.9K Hold
500
– – 0.01% 202
2026
Q1 		$25.4K Hold
500
– – 0.01% 241
2025
Q4 		$15.4K Hold
500
– – 0.01% 267
2025
Q3 		$13.8K Buy
500
+450
+900% +$12.6K ﹤0.01% 299
2025
Q2 		$1.36K Hold
50
– – ﹤0.01% 491
2025
Q1 		$1.29K Sell
50
-100
-67% -$3.55K ﹤0.01% 474
2024
Q4 		$6.3K Sell
150
-30
-17% -$1.43K ﹤0.01% 360
2024
Q3 		$12K Hold
180
– – 0.01% 341
2024
Q2 		$20.9K Buy
180
+30
+20% +$3.8K 0.01% 295
2024
Q1 		$16.5K Sell
150
-50
-25% -$5.04K 0.01% 313
2023
Q4 		$15.7K Hold
200
– – 0.01% 325
2023
Q3 		$20.6K Buy
200
+150
+300% +$16.7K 0.01% 282
2023
Q2 		$6.18K Sell
50
-15
-23% -$2K ﹤0.01% 349
2023
Q1 		$10.2K Buy
65
+15
+30% +$2.48K 0.01% 305
2022
Q4 		$9.02K Hold
50
– – 0.01% 293
2022
Q3 		$7K Buy
50
+20
+67% +$3.04K 0.01% 334
2022
Q2 		$4K Buy
+30
New +$4.29K ﹤0.01% 392

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Pacifica Partners's MRNA Position: Q2 2026 in Review

Pacifica Partners held its Moderna (MRNA) position steady in Q2 2026 at 500 shares worth $39.9K. The position accounts for 0.01% of the portfolio, ranked #202.

Pacifica Partners first reported a position in MRNA in Q2 2022 and has held it in 17 quarters since. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Pacifica Partners held 500 shares of Moderna worth $39.9K as of Q2 2026.
  • Pacifica Partners left its Moderna share count unchanged in Q2 2026.
  • Moderna made up 0.01% of Pacifica Partners's portfolio in Q2 2026, its #202 holding.
  • Pacifica Partners first reported a position in Moderna in Q2 2022 and has held it in 17 quarters since.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Pacifica Partners's 13F filing for Q2 2026, filed 13 Jul 2026.